Accessibility Menu
Winston Pharmaceuticals logo

Winston Pharmaceuticals(OTC) WPHM

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-100%
1 Year+0%
1 Month-99%
$0.00
+0%
+0.00Today
Winston Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-04-29
Winston Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002026-03-09
1 month-99%USD 0.002026-03-09
3 month-99%USD 0.002025-11-10
Year to date-99%USD 0.002025-11-10
1 year+0%USD 0.002025-02-20
3 year-100%USD 0.302022-08-04
5 year-100%USD 0.092021-04-30
Since inception-100%USD 6.802008-09-26

Winston Pharmaceuticals Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.37M

Net Income (TTM)

-$2.34M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3265.96 (High)

Price

$0.00

Volume

125

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

WPHM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Winston Pharmaceuticals

Winston Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative treatments for various pain conditions. The company addresses a wide range of painful ailments, including migraines, neuropathic pain, and arthritis-related discomfort.

Products and Services
  • Innovative treatments for episodic cluster headaches
  • Therapies for chronic migraines and neuropathic pain syndromes
  • Solutions for pain and inflammation associated with inflammatory bowel disease
Growth Outlook
  • Strong pipeline targeting diverse pain conditions enhances market potential
  • Established operations in Vernon Hills, Illinois, support efficient development
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Recent quarterly revenue of 316,706 reflects ongoing operational activities
  • Trailing twelve months (TTM) gross profit margin stands at 99.35%
  • Current ratio of 1.39 indicates solid short-term financial health
Winston Pharmaceuticals, Inc. has a dedicated focus on addressing significant pain management needs through its innovative product offerings. The company's strong gross profit margin suggests effective cost management and operational efficiency. The current ratio indicates a healthy liquidity position, allowing for continued investment in research and development. With a robust pipeline and a commitment to addressing various pain conditions, Winston Pharmaceuticals is well-positioned for future growth in the biopharmaceutical sector.
AI Generated • Jul 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Vernon Hills, IL 60061, US

WPHM Financials

Key Financial Metrics (TTM)

Gross Margin

99.35%

Operating Margin

-196.56%

Net Income Margin

-190.40%

Return on Equity

-156.02%

Return on Capital

-561.07%

Return on Assets

-158.43%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.41M

Volume

125

Avg. Volume

2.016

Financials (TTM)

Gross Profit

$1.37M

Operating Income

-$2.41M

EBITDA

-$2.41M

Operating Cash Flow

-$3.54M

Capital Expenditure

-$2.17K

Free Cash Flow

-$3.54M

Cash & ST Invst.

$677.52K

Total Debt

$0.00

Winston Pharmaceuticals Performance Analysis

Winston Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22009-06-307.4%
Q32009-09-30-4.0%
Q42009-12-31-3.3%
Q12010-03-31-6.6%
Winston Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22009-06-30N/A
Q32009-09-30N/A
Q42009-12-31100.0%
Q12010-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2010YOY CHG

Revenue

$316.71K

-6.8%

Gross Profit

$316.71K

-6.8%

Gross Margin

100.00%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.11

N/A

Employees

9

N/A

Net Income

-$460.69K

+40.8%

EBITDA

-$459.40K

+41.6%

Quarterly Fundamentals

Name
Q1 2010YOY CHG

Total Cash

$677.52K

-83.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$28.93K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.58%

N/A

Return on Invested Capital

-5.61%

N/A

Free Cash Flow

-$885.33K

+42.5%

Operating Cash Flow

-$883.43K

+42.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DMSIDermisonics, Inc.
$0.00+0.00%
AFIBAcutus Medical, Inc.
$0.00+0.00%
ALSTAllStar Health Brands Inc
$0.00-33.33%
IYXIInyx, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About WPHM

What is the current price of Winston Pharmaceuticals?

Winston Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Winston Pharmaceuticals?

Over the past 52 weeks, Winston Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Winston Pharmaceuticals have?

Winston Pharmaceuticals total debt is unavailable.

How much cash does Winston Pharmaceuticals have on hand?

Winston Pharmaceuticals does not have cash on hand data available.

What is Winston Pharmaceuticals’s dividend yield?

Winston Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services